Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,756 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions: Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%; Drug · Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Weeks to 27 Weeks
Enrollment: 1,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more

Conditions: Asthma
Interventions: MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Budesonide inhalation suspension 0.5mg; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Acute Kidney Injury
Interventions: RMC-035, Placebo; Drug
Lead sponsor: Guard Therapeutics AB; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more

Conditions: Laryngeal Diseases
Interventions: CO2 laser; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 88 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: Fentanyl, oxycodone/acetaminophen; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: High Risk for Developing Breast Cancer
Interventions: Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions: AL58805, AL3818, Temozolomide (TMZ), CCNU; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Feasibility Pilot Study, Compliance
Interventions: Biospecimen Collection, Dietary Intervention, Medical Device Usage and Evaluation, Motivational Interviewing, Nutritional Assessment, Questionnaire Administration; Procedure · Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Low Back Pain, Veterans Family
Interventions: Pain modulation with physical pain treatment, Telephone delivered self-management counseling for increasing physical activity, Telephone delivered behavioral treatment for participants with high risk for continued disability, Patient preference treatment protocol, Nonpharmacological guideline adherent treatment protocol, Facilitated referrals to existing VA or non-VA pain management resources; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,817 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tobacco Use Disorder
Interventions: smoking cessation intervention, cancer prevention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, survey administration, study of high risk factors; Behavioral · Other · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions: Pemziviptadil (PB1046), Low Dose (10 mg) Control; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more

Conditions: Prostate Cancer
Interventions: high resolution MRI (hrMRI); Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 19 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: CoQ10 Blood Levels
Interventions: high absorption CoQ10 product, standard CoQ10 product; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
Interventions: fluorothymidine F 18; Drug
Lead sponsor: John M. Buatti; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education; Drug · Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 12 Years to 25 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more

Conditions: Leukemia
Interventions: cytarabine, idarubicin, lestaurtinib; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 18 more

Conditions: Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions: Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Obesity
Interventions: meal replacements, psychotherapy, dietary education; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy); Drug
Lead sponsor: enGene, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more

Conditions: Ulcerative Colitis (UC)
Interventions: Adalimumab, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more

Conditions: Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions: Moderate intensity exercise training (MOD-INT), High Intensity exercise training (HI-INT); Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Advanced Solid Tumor
Interventions: STX-003, KEYTRUDA®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee

Search by objective public record fields.

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

A Study of 2 Doses of MAP0010 in Adult Asthmatics

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Comparison of Office-based KTP and CO2 Laser Outcomes in Patients With Vocal Cord Lesions.

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women

Improving Veteran Access to Integrated Management of Back Pain

Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

High Resolution MRI Study for Prostate Cancer

Assessing Two Coenzyme Q10 Products in Men and Women

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

Early Detection and Intervention for the Prevention of Psychosis

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

Brain, Obesity, Dopamine and You Study

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab